Business Description
Corcept Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US2183521028
Share Class Description:
CORT: Ordinary SharesDescription
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2438.55 | |||||
| Equity-to-Asset | 0.82 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 15.34 | |||||
| Beneish M-Score | -2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.9 | |||||
| 3-Year EBITDA Growth Rate | -2.2 | |||||
| 3-Year EPS without NRI Growth Rate | 3.4 | |||||
| 3-Year FCF Growth Rate | -2.2 | |||||
| 3-Year Book Growth Rate | 3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 17.22 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.12 | |||||
| 9-Day RSI | 32.4 | |||||
| 14-Day RSI | 38.34 | |||||
| 6-1 Month Momentum % | -14.07 | |||||
| 12-1 Month Momentum % | 9.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.39 | |||||
| Quick Ratio | 4.31 | |||||
| Cash Ratio | 3.52 | |||||
| Days Inventory | 390.42 | |||||
| Days Sales Outstanding | 26.02 | |||||
| Days Payable | 735.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 4 | |||||
| Shareholder Yield % | 0.08 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.66 | |||||
| Operating Margin % | 22.24 | |||||
| Net Margin % | 22 | |||||
| FCF Margin % | 26.34 | |||||
| ROE % | 21.92 | |||||
| ROA % | 18.04 | |||||
| ROIC % | 68.03 | |||||
| ROC (Joel Greenblatt) % | 12606.58 | |||||
| ROCE % | 21.71 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.87 | |||||
| Forward PE Ratio | 147.06 | |||||
| PE Ratio without NRI | 23.87 | |||||
| Shiller PE Ratio | 34.5 | |||||
| Price-to-Owner-Earnings | 29.04 | |||||
| PEG Ratio | 4.42 | |||||
| PS Ratio | 5.25 | |||||
| PB Ratio | 4.63 | |||||
| Price-to-Tangible-Book | 4.63 | |||||
| Price-to-Free-Cash-Flow | 19.89 | |||||
| Price-to-Operating-Cash-Flow | 19.89 | |||||
| EV-to-EBIT | 18.52 | |||||
| EV-to-EBITDA | 18.12 | |||||
| EV-to-Revenue | 4.12 | |||||
| EV-to-Forward-Revenue | 3.23 | |||||
| EV-to-FCF | 15.64 | |||||
| Price-to-Projected-FCF | 1.05 | |||||
| Price-to-Median-PS-Value | 0.61 | |||||
| Price-to-Graham-Number | 2.23 | |||||
| Price-to-Net-Current-Asset-Value | 6.81 | |||||
| Price-to-Net-Cash | 9.26 | |||||
| Earnings Yield (Greenblatt) % | 5.4 | |||||
| FCF Yield % | 5.39 | |||||
| Forward Rate of Return (Yacktman) % | 9.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CORT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Corcept Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 482.375 | ||
| EPS (TTM) ($) | 0.95 | ||
| Beta | 0.41 | ||
| Volatility % | 62.05 | ||
| 14-Day RSI | 38.34 | ||
| 14-Day ATR ($) | 0.916279 | ||
| 20-Day SMA ($) | 24.4815 | ||
| 12-1 Month Momentum % | 9.75 | ||
| 52-Week Range ($) | 20.8693 - 34.275 | ||
| Shares Outstanding (Mil) | 103.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corcept Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corcept Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Corcept Therapeutics Inc Frequently Asked Questions
What is Corcept Therapeutics Inc(CORT)'s stock price today?
The current price of CORT is $22.68. The 52 week high of CORT is $34.28 and 52 week low is $20.87.
When is next earnings date of Corcept Therapeutics Inc(CORT)?
The next earnings date of Corcept Therapeutics Inc(CORT) is 2024-05-03 Est..
Does Corcept Therapeutics Inc(CORT) pay dividends? If so, how much?
Corcept Therapeutics Inc(CORT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers